93071-65-9

Basic information

• Product Name: Methyl3-(aminomethyl)benzoate
• Synonyms: Benzoic acid, 3-(aMinoMethyl)-, Methyl ester;3-Aminomethyl-benzoic acid methyl ester≥ 98% (GC);Methyl3-(aminomethyl)benzoate;3-(Aminomethyl)benzoic acid methyl ester
• CAS NO: 93071-65-9
• Molecular Formula: C₉H₁₁NO₂
• Molecular Weight: 165.19
• Mol File: 93071-65-9.mol
• Article Data: 14

Chemical Properties

• Melting Point: 37-39 ºC
• Boiling Point: 280 ºC
• Flash Point: 139 ºC
• Appearance: /
• Density: 1.121
• Storage Temp.: 2-8°C
• PKA: 8.76±0.10(Predicted)
• CAS DataBase Reference: Methyl3-(aminomethyl)benzoate(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl3-(aminomethyl)benzoate(93071-65-9)
• EPA Substance Registry System: Methyl3-(aminomethyl)benzoate(93071-65-9)

Safety Data

• Hazardous Substances Data: 93071-65-9(Hazardous Substances Data)

Upstream product

• 67-56-1 methanol 
• 876-03-9 3-(aminomethyl)benzoic acid hydrochloride 
• 13531-48-1 methyl 3-cyanobenzoate 
• 180863-55-2 methyl 3-(((tert-butoxycarbonyl)amino)methyl)benzoate 
• 781632-38-0 3-(1, 3-Dioxo-1,3-dihydro-isoindol-2-ylmethyl)-benzoic acid methyl ester 
• 99-04-7 m-Toluic acid 
• 2393-20-6 3-aminomethylbenzoic acid 
• 1877-72-1 3-Cyanobenzoic acid 
• 1129-28-8 3-methoxycarbonylbenzyl bromide 
• 99-36-5 1-methoxycarbonyl-3-methylbenzene 
• 180863-54-1 methyl 3-(azidomethyl)benzoate 

Downstream Products

• 153938-43-3 methyl 3-(phthalimido-N-acetamidomethyl)benzoate 
• 858781-01-8 3-({[(R)-3-((2S,3S)-3-tert-Butoxycarbonylamino-2-hydroxy-4-phenyl-butyryl)-5,5-dimethyl-thiazolidine-4-carbonyl]-amino}-methyl)-benzoic acid methyl ester 
• 208450-86-6 di(3-methoxycarbonylphenylmethyl)amine 
• 1258652-11-7 C₂₇H₂₇NO₆ 
• 1273318-19-6 methyl 3-(((2,4,6-trimethylphenyl)sulfonamido)methyl)benzoate 

Relevant articles and documents

The development of a novel transforming growth factor-β (TGF-β) inhibitor that disrupts ligand-receptor interactions

Transforming growth factor-β (TGF-β) plays an important role in regulating epithelial to mesenchymal transition (EMT) and the TGF-β signaling pathway is a potential target for therapeutic intervention in the development of many diseases, such as fibrosis and cancer. Most currently available inhibitors of TGF-β signaling function as TGF-β receptor I (TβR-I) kinase inhibitors, however, such kinase inhibitors often lack specificity. In the present study, we targeted the extracellular protein binding domain of the TGF-β receptor II (TβR-II) to interfere with the protein-protein interactions (PPIs) between TGF-β and its receptors. One compound, CJJ300, inhibited TGF-β signaling by disrupting the formation of the TGF-β-TβR-I-TβR-II signaling complex. Treatment of A549 cells with CJJ300 resulted in the inhibition of downstream signaling events such as the phosphorylation of key factors along the TGF-β pathway and the induction of EMT markers. Concomitant with these effects, CJJ300 significantly inhibited cell migration. The present study describes for the first time a designed molecule that can regulate TGF-β-induced signaling and EMT by interfering with the PPIs required for the formation of the TGF-β signaling complex. Therefore, CJJ300 can be an important lead compound with which to study TGF-β signaling and to design more potent TGF-β signaling antagonists.

Identification of ortho-Substituted Benzoic Acid/Ester Derivatives via the Gas-Phase Neighboring Group Participation Effect in (+)-ESI High Resolution Mass Spectrometry

Benzoic acid/ester/amide derivatives are common moieties in pharmaceutical compounds and present a challenge in positional isomer identification by traditional tandem mass spectrometric analysis. A method is presented for exploiting the gas-phase neighbor

5-LIPOXYGENASE INHIBITORS

The present invention relates to pyrazole derivatives of formula 1 and to process as for their synthesis as 5-lipoxygenase (5-LO) inhibitors. The present invention also relates to pharmacological compositions containing these pyrazole derivatives, as well as, methods of treating bronchial asthma, chronic obstructive pulmonary disease, rheumatoid arthritis, multiple sclerosis, Type I diabetes, psoriasis, allograft rejection, inflammatory bowel disease, ulcerative colitis, acne, atherosclerosis, cancer, pruritis, allergic rhinitis and other inflammatory and/or autoimmune disorders.